Tan Yang

Dr. Tan Yang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Biomaterials
Verified
Journal Article
Closed access
XZXiaojuan Zhang
Xiaojuan Zhang
CHChuanchuan He
Chuanchuan He
YCYan Chen
Yan Chen
CCChen Chen
Chen Chen
RYRuicong Yan
Ruicong Yan
GXGuangya Xiang
Guangya Xiang

1 June 2020 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YCYan Chen
Yan Chen
CCChen Chen
Chen Chen
XZXiaojuan Zhang
Xiaojuan Zhang
CHChuanchuan He
Chuanchuan He
PZPengxuan Zhao
Pengxuan Zhao
GXGuangya Xiang
Guangya Xiang
Platinum-based chemotherapy is used for non-small cell lung cancer (NSCLC). However, it has side effects and minimum efficacy against lung cancer metastasis. In this study, platinum–curcumin complexes were loaded into pH and redox dual-responsive nanoparticles (denoted as Pt–CUR@PSPPN) to facilitate intracellular release and synergistic anti-cancer effects. Pt–CUR@PSPPN was prepared by a nano-precipitation method and had a diameter of ∼100 nm. The nanoparticles showed increased anti-cancer effects both in vivo and in vitro. In addition, Pt–CUR@PSPPN blocked PI3K/AKT signal transduction pathway and inhibited MMP2 and VEGFR2, resulting in enhanced anti-metastatic activity. Furthermore, reduced side effects were also observed. In conclusion, Pt–CUR@PSPPN provided a novel and attractive therapeutic strategy for NSCLC.

1 March 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
CHChuanchuan He
Chuanchuan He
XZXiaojuan Zhang
Xiaojuan Zhang
CCChen Chen
Chen Chen
XLXiaoguang Liu
Xiaoguang Liu
YCYan Chen
Yan Chen
GXGuangya Xiang
Guangya Xiang

15 January 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TYTao Yang
Tao Yang
ZDZhengdong Deng
Zhengdong Deng
LXLei Xu
Lei Xu
XLXiangyu Li
Xiangyu Li
TYTan Yang
Tan Yang
JWJianming Wang
Jianming Wang
Background: Recent data indicated that macrophages may mutually interact with cancer cells to promote tumor progression and chemoresistance, but the interaction in cholangiocarcinoma (CCA) is obscure. Methods: 10x Genomics single-cell sequencing technology was used to identified the role of macrophages in CCA. Then, we measured the expression and prognostic role of macrophage markers and aPKCɩ in 70 human CCA tissues. Moreover, we constructed monocyte-derived macrophages (MDMs) generated from peripheral blood monocytes (PBMCs) and polarized them into M1/M2 macrophages. A co-culture assay of the human CCA cell lines (TFK-1, EGI-1) and differentiated PBMCs-macrophages was established, and functional studies in vitro and in vivo was performed to explore the interaction between cancer cells and M2 macrophages. Furthermore, we established the cationic liposome-mediated co-delivery of gemcitabine and aPKCɩ-siRNA and detect the antitumor effects in CCA. Results: M2 macrophage showed tumor-promoting properties in CCA. High levels of aPKCɩ expression and M2 macrophage infiltration were associated with metastasis and poor prognosis in CCA patients. Moreover, CCA patients with low M2 macrophages infiltration or low aPKCɩ expression benefited from postoperative gemcitabine-based chemotherapy. Further studies showed that M2 macrophages-derived TGFβ1 induced epithelial-mesenchymal transition (EMT) and gemcitabine resistance in CCA cells through aPKCɩ-mediated NF-κB signaling pathway. Reciprocally, CCL5 was secreted more by CCA cells undergoing aPKCɩ-induced EMT and consequently modulated macrophage recruitment and polarization. Furthermore, the cationic liposome-mediated co-delivery of GEM and aPKCɩ-siRNA significantly inhibited macrophages infiltration and CCA progression. Conclusion: our study demonstrates the role of Macrophages-aPKCɩ-CCL5 Feedback Loop in CCA, and proposes a novel therapeutic strategy of aPKCɩ-siRNA and GEM co-delivered by liposomes for CCA.

1 November 2015 in Enzyme and Microbial Technology
Verified
Journal Article
Closed access
TYTan Yang
Tan Yang
ZLziyong Liu
ziyong Liu
ZLZhen Liu
Zhen Liu
FLFu-Li Li
Fu-Li Li

18 October 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
WLWeijie Li
Weijie Li
HWHan Wang
Han Wang
YLYong Liu
Yong Liu
BLBin Li
Bin Li
FWFei Wang
Fei Wang
TYTan Yang
Tan Yang